{"doi":"10.1016\/j.ijpharm.2006.02.040","coreId":"135332","oai":"oai:bradscholars.brad.ac.uk:10454\/4128","identifiers":["oai:bradscholars.brad.ac.uk:10454\/4128","10.1016\/j.ijpharm.2006.02.040"],"title":"Emitted dose estimates from Seretide\u00ae Diskus\u00ae and Symbicort\u00ae Turbuhaler\u00ae following inhalation by severe asthmatics","authors":["Assi, Khaled H.","Chrystyn, H.","Pearson, S.B.","Tarsin, W."],"enrichments":{"references":[],"documentType":{"type":null}},"contributors":[],"datePublished":"2006","abstract":"NoThe dose emitted from dry powder inhalers may be inhalation flow-dependent. Using an ex vivo method, the Electronic Lung\u00bf, we have measured the aerodynamic characteristics of the emitted dose for both active constituents from Seretide\u00ae Diskus\u00ae (salmeterol xinafoate 50 mcg; fluticasone propionate 500 mcg) and Symbicort\u00ae Turbuhaler\u00ae (formoterol 6 mcg; budesonide 200 mcg).1 Electronic inhalation profiles were collected from 20 severe asthmatics (mean PEFR 53% predicted) when they inhaled using a placebo Seretide\u00ae Diskus\u00ae and a placebo Symbicort\u00ae Turbuhaler\u00ae. These were replayed in the Electronic Lung\u00bf with the respective active inhaler in situ. Mean(S.D.) peak inhalation flow rates (PIFR) through the Diskus\u00ae and Turbuhaler\u00ae were 94.7(32.9) and 76.8(26.2) l min\u00bf1, respectively. From the Electronic Lung\u00bf the Diskus\u00ae inhalation profiles provided a mean(S.D.) fine particle dose (FPD) for fluticasone propionate and salmeterol of 20.4(4.8) and 18.4(4.4)% labelled dose. For Turbuhaler\u00ae inhalation profiles the FPD was 23.1(12.9) and 20.7(11.1)% labelled dose for budesonide and formoterol, respectively. The linear (p < 0.001) relationships between FPD against PIFR for budesonide and formoterol were 3 (p = 0.002) and 2.8 (p = 0.007) times steeper than fluticasone propionate and salmeterol, respectively. The results highlight a more significant effect of inspiratory flow on variable dosage emission when using the Symbicort\u00ae Turbuhaler\u00ae compared with the Seretide\u00ae Diskus\u00ae","downloadUrl":"","fullTextIdentifier":null,"pdfHashValue":null,"publisher":null,"rawRecordXml":"<record><header><identifier>\n        \n            \n                oai:bradscholars.brad.ac.uk:10454\/4128<\/identifier><datestamp>\n                2016-08-18T17:06:12Z<\/datestamp><setSpec>\n                com_10454_152<\/setSpec><setSpec>\n                col_10454_6342<\/setSpec>\n            <\/header><metadata><oai_dc:dc xmlns:oai_dc=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/\" xmlns:dc=\"http:\/\/purl.org\/dc\/elements\/1.1\/\" xmlns:doc=\"http:\/\/www.lyncode.com\/xoai\" xmlns:xsi=\"http:\/\/www.w3.org\/2001\/XMLSchema-instance\" xsi:schemaLocation=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/ http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc.xsd\" ><dc:title>\n            \nEmitted dose estimates from Seretide\u00ae Diskus\u00ae and Symbicort\u00ae Turbuhaler\u00ae following inhalation by severe asthmatics<\/dc:title><dc:creator>\nAssi, Khaled H.<\/dc:creator><dc:creator>\nChrystyn, H.<\/dc:creator><dc:creator>\nPearson, S.B.<\/dc:creator><dc:creator>\nTarsin, W.<\/dc:creator><dc:subject>\nDiskus\u00ae<\/dc:subject><dc:subject>\nTurbuhaler\u00ae<\/dc:subject><dc:subject>\nElectronic Lung\u00bf<\/dc:subject><dc:subject>\nDose<\/dc:subject><dc:subject>\nAsthma<\/dc:subject><dc:description>\nNo<\/dc:description><dc:description>\nThe dose emitted from dry powder inhalers may be inhalation flow-dependent. Using an ex vivo method, the Electronic Lung\u00bf, we have measured the aerodynamic characteristics of the emitted dose for both active constituents from Seretide\u00ae Diskus\u00ae (salmeterol xinafoate 50 mcg; fluticasone propionate 500 mcg) and Symbicort\u00ae Turbuhaler\u00ae (formoterol 6 mcg; budesonide 200 mcg).1 Electronic inhalation profiles were collected from 20 severe asthmatics (mean PEFR 53% predicted) when they inhaled using a placebo Seretide\u00ae Diskus\u00ae and a placebo Symbicort\u00ae Turbuhaler\u00ae. These were replayed in the Electronic Lung\u00bf with the respective active inhaler in situ. Mean(S.D.) peak inhalation flow rates (PIFR) through the Diskus\u00ae and Turbuhaler\u00ae were 94.7(32.9) and 76.8(26.2) l min\u00bf1, respectively. From the Electronic Lung\u00bf the Diskus\u00ae inhalation profiles provided a mean(S.D.) fine particle dose (FPD) for fluticasone propionate and salmeterol of 20.4(4.8) and 18.4(4.4)% labelled dose. For Turbuhaler\u00ae inhalation profiles the FPD was 23.1(12.9) and 20.7(11.1)% labelled dose for budesonide and formoterol, respectively. The linear (p < 0.001) relationships between FPD against PIFR for budesonide and formoterol were 3 (p = 0.002) and 2.8 (p = 0.007) times steeper than fluticasone propionate and salmeterol, respectively. The results highlight a more significant effect of inspiratory flow on variable dosage emission when using the Symbicort\u00ae Turbuhaler\u00ae compared with the Seretide\u00ae Diskus\u00ae.<\/dc:description><dc:date>\n2009-12-17T13:49:41Z<\/dc:date><dc:date>\n2009-12-17T13:49:41Z<\/dc:date><dc:date>\n2006<\/dc:date><dc:type>\nArticle<\/dc:type><dc:type>\nNo full-text available in the repository<\/dc:type><dc:identifier>\nAssi, K.H., Chrystyn, H., Pearson, S.B. and Tarsin, W. (2006). Emitted dose estimates from Seretide\u00ae Diskus\u00ae and Symbicort\u00ae Turbuhaler\u00ae following inhalation by severe asthmatics. International Journal of Pharmaceutics. Vol. 316, No. 1-2, pp. 131-137.<\/dc:identifier><dc:identifier>\n90006689<\/dc:identifier><dc:identifier>\nhttp:\/\/hdl.handle.net\/10454\/4128<\/dc:identifier><dc:language>\nen<\/dc:language><dc:relation>\nhttp:\/\/dx.doi.org\/10.1016\/j.ijpharm.2006.02.040<\/dc:relation>\n<\/oai_dc:dc>\n<\/metadata>\n        <\/record>","journals":null,"language":null,"relations":["http:\/\/dx.doi.org\/10.1016\/j.ijpharm.2006.02.040"],"year":2006,"topics":["Diskus\u00ae","Turbuhaler\u00ae","Electronic Lung\u00bf","Dose","Asthma"],"subject":["Article","No full-text available in the repository"],"fullText":null}